Board Reconstitution and Nasdaq Compliance
23andMe reconstituted its Board of Directors with three new Independent Directors and regained compliance with Nasdaq listing standards.
Significant Progress in Subscription Services
The company more than doubled its recurring revenue percentage from 9% in the prior year quarter to over 21% in Q2.
Launch of Total Health Membership Service
Introduced a comprehensive longevity platform combining advanced exome sequencing, lab tests, and genetics-focused clinician guidance.
New Genetic Studies and Reports
Launched studies on GLP-1 efficacy and genetic reports on emotional eating, along with improvements to ancestry composition and historical matches features.
Improved Financial Metrics
Improved GAAP net loss by 21% and adjusted EBITDA by 26% compared to the same period in the prior year.